Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Advanced or Metastatic Solid Tumors

NCT07021066 is registered in ClinicalTrials.gov with SystImmune Inc. as lead sponsor.

NCT NCT07021066
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07021066 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Advanced or Metastatic Solid Tumors
Lead sponsor
SystImmune Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
July 30, 2025
Completion date
May 31, 2027
Enrollment
160 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

advanced pancreatic ductal adenocarcinoma, biliary tract cancer, esophageal adenocarcinoma, gastric adenocarcinoma, other solid tumors